Dr. Terence Rooney, Vice President, Rheumatology & Maternal-Fetal Immunology Disease Area Leader at Janssen discusses Janssen’s announcement of a comprehensive Network Meta-Analysis (NMA) at Maui Dermatology which concluded that TREMFYA ® (guselkumab) ranked highest for the overall level of skin clearance and showed positive joint efficacy among all advanced therapies approved for the treatment of active psoriatic arthritis (PsA). He talks about what this new data means for patients and why understanding the landscape of treatment options in active PsA is important for physicians making decisions about patient care. 

Terence Rooney, M.D., is Vice President, Rheumatology and Maternal-Fetal Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in the rheumatology and maternal-fetal disease area, overseeing innovative compounds across multiple phases of development.

Terence received his medical degrees from the Royal College of Surgeons in Ireland. During 10 years of academic clinical practice at teaching hospitals in Dublin, he completed postgraduate training in Rheumatology and Internal Medicine. His clinical/translational research fields of interest included rheumatoid arthritis biomarkers for the evolving targeted therapy era, in which he acquired a doctoral degree. He completed a post-fellowship attachment at the University of California San Francisco Division of Rheumatology before transitioning to work full time in pharmaceutical research and development.

Liked it? Take a second to support healthprofessionalradio on Patreon!